



CERTIFICATE OF MAILING

HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT
POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-
1450, ON January 6, 2006

Audrey Boyd
January 6, 2006
DATE

Attorney Docket No. P32181C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Lewis et al. January 6, 2006
Serial No.: 10/691,159 Group Art Unit No.: 1618
Filed: October 22, 2003 Examiner: N. G. Ebrahim
For: PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE OF AN
INSULIN SENSITISER AND ANOTHER ANTIDIABETIC AGENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


FILING OF A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,


Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
N:\kls\cases\p32181C1\Supp IDS Letter 2.doc



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
P32181C1SERIAL NO.
10/691,159**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT***(Use several sheets if necessary)*APPLICANT
Lewis et al.FILING DATE
October 22, 2003GROUP
1618**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	6,340,475	1/22/02	Shell et al.	424	469	
	6,488,962	12/3/02	Berner et al.	424	484	
	6,723,340	4/20/04	Gusler et al.	424	468	
	6,790,459	9/14/04	Cheng et al.	424	468	
	6,866,866	3/15/05	Chen et al.	424	468	
	6,099,859	8/8/00	Cheng et al.	424	464	
	6,495,162	12/17/02	Cheng et al.	424	464	
	6,303,146	10/16/01	Bonhomme et al.	424	465	
	6,890,957	5/10/05	Chandran et al.	514	634	
	6,475,521	11/5/02	Timmins et al.	424	469	
	6,660,300	12/9/03	Timmins et al.	424	469	
	5,965,584	10/12/99	Ikeda et al.	514	342	

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	Longer et al., "Sustained-Release Drug Delivery Systems," Chapter 92, Remington's Pharmaceutical Sciences, pp. 1644-1661 (1987).
	Methocel: Product Specifications, 2005, http://www.colorcon.com/pharma/mod_rel/methocel/literature/methocel_k4m_cr.pdf
	"Practical Course in Film Coating of Pharmaceutical Dosage Forms with EUDRAGIT®". http://www.roehm.de/en/pharmapolymers?content=/en/pharmapolymers/service/literature/practical_course March 2000
	Schminke et al. "Enteric Film Coatings with Polymethacrylates". 31 st International EUDRAGIT® Workshop, 2000.
	EUDRAGIT® L 30 D Aqueous Acrylic Polymer Dispersion Information Sheet. April 2000
	EUDRAGIT® NE 30 D Aqueous Acrylic Polymer Dispersion Information Sheet. April 2000

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.